GLG News Analyses of the following article:
Positive Phase II AGI-004 proof of concept study
Published at: www.msnbc.msn.com
-
Transdermal Patch with AGI-004 Reduces Chemo-Induced Diarrhea (CID)
March 16, 2009
In addition to dimishing quality of life, Chemotherpy-Induced Diarrhea (CID) can reduce our ability to administer full doses of potentially effective tretaments, and can occasionally lead to life-threatening complications. AGI-004 was studied in the form of a skin patch, and when compared to placebo, diminished frequency and intensity of CID.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.